Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 14/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336156 | 1.00 | CYP11B1 (0.47) | CYP11B1CYP11B2GRM4NR3C2RIPK1 | |
| SCHEMBL21500799 | 0.84 | RIPK1 (0.39) | RIPK1 | |
| SCHEMBL30250877 | 0.84 | RIPK1 (0.39) | RIPK1 | |
| SCHEMBL12963725 | 0.80 | ADRA2A (0.47) | CHRM1DRD2KCNH2 | |
| SCHEMBL18237838 | 0.80 | USP19 (0.41) | NR3C2CHRM1DRD2KCNH2 | |
| SCHEMBL18937273 | 0.80 | USP19 (0.38) | CYP11B1CYP11B2GRM4NR3C2TERT | |
| SCHEMBL19228337 | 0.78 | RIPK1 (0.42) | RIPK1 | |
| SCHEMBL11034464 | 0.77 | NOS3 (0.41) | CHRM1DRD2KCNH2 | |
| SCHEMBL19153681 | 0.77 | CYP11B2 (0.41) | CYP11B1CYP11B2GRM4TERT | |
| SCHEMBL5226380 | 0.76 | NR3C2 (0.39) | NR3C2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| US-7812158-B2 | Coupling agents for peptide synthesis | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| US-20070112196-A1 | New coupling agents for peptide synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-17 | — | — | US | disclosed |
| EP-0462813-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-10-25 | — | — | EP | disclosed |
| US-5373007-A | Lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-12-13 | — | — | US | disclosed |
| US-5321025-A | Inhibitors of 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-06-14 | — | — | US | disclosed |
| US-5217969-A | Antiinflammatory, antiulcer agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| EP-0462813-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CYP11B1 4104/4885CYP11B2 4026/4885GRM4 2092/4885 |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | CYP11B1 3076/4885CYP11B2 3496/4885GRM4 4663/4885 |
| US-20070112196-A1 | New coupling agents for peptide synthesis | NGLY1, NPPA, VIP | CYP11B1 2691/4885CYP11B2 2574/4885GRM4 3468/4885 |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | CYP11B1 897/4885CYP11B2 623/4885GRM4 770/4885 |
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | CYP11B1 334/4885CYP11B2 278/4885GRM4 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.